SOHM Inc. (OTC:SHMN) Stock Resumes Uptrend: What Next?
There were a number of companies that had been in the news for a variety of reasons, and one of those was SOHM Inc. (OTC:SHMN). The company, which is involved in the pharmaceutical, cosmeceutical, and nutraceutical spaces, is also engaged in the manufacturing and marketing of generic drugs for numerous treatments.
On August 24, it came into the news cycle after it announced that it had appointed a new Chief Medical Advisor to its Advisory Board in the form of Dr. Krishna Bhat, MD, Ph.D., FACC. Dr. Bhat is a cardiologist and bioscientist with considerable experience. It was a significant new announcement for SOHM, especially because the company is involved in spaces that are driven by innovation and inventiveness.
The President and Chief Executive Officer of the company, Baron Night, spoke about the appointment as well and provided interested parties with an insight into Dr. Bhat’s credentials. He noted that Dr. Bhat had been involved with a cardiology practice for more than 35 years in the clinical and interventional cardiology space. Additionally, he had also been bestowed with the Hall of Fame Award for 2021 by the American Heart Association.
Additionally, the Montreal Heart Institute had bestowed him with the J. Louis Levesque Fellowship Award, and he had also won the Miles Canada Fellowship Award. Night also stated that everyone at SOHM was delighted at Dr. Bhat’s induction into the Advisory Board of the company. In the new role, he would be responsible for supporting the company following the anticipated acquisition of ABBIE Technology and its novel patents, cardiac treatments, diagnostic kits, and clinical trials. Dr. Bhat also expressed his delight at having joined SOHM and went on to note that, as a long-term shareholder in the company, he had been impressed with the growth and progress that the company had achieved.
On August 8, the company was in the news after it announced another new appointment. That time, the appointment was that of Dr. David Aguilar, Ph.D., as the Chief Operating Officer of the company. The appointment went into effect immediately. Dr. Aguilar is a highly experienced professional with experience spanning 22 years in the pharmaceutical industry.
Additionally, he had also been involved with a number of publications and research papers. Perhaps more importantly, the company noted at the time that Dr. Aguilar held considerable experience in preclinical and investigational new drug applications for allogeneic cell-based therapeutics. The news release also noted that he had significant experience and understanding of the regulations and the clinical pathways in place.
Once combined with his strong technical and scientific grounding, Dr. Aguilar could be seen as a formidable candidate for the role of COO. The company claimed that he would provide a unique angle on the development of new assets from conception to the delivery of the same to clinics. Baron Night praised Dr. Aguilar for his business skills, talent, and considerable institutional knowledge of SOHM in his statement about the appointment.
